Author: admin

Moderna researchers at work in the company’s lab. The FDA’s reversal of its earlier refusal to review mRNA-1010, the seasonal flu vaccine being developed by Moderna accelerated a revival of its shares that has been in progress over recent months—but the rebound has not lifted the prices of other vaccine stocks. [Moderna] The FDA’s reversal of its earlier refusal to review mRNA-1010, the seasonal flu vaccine being developed by Moderna (NASDAQ: MRNA), accelerated a revival of Moderna shares that has been in progress over recent months—but the rebound has not lifted the prices of other vaccine stocks. Moderna announced Wednesday…

Computer illustration of a lipid nanoparticle mRNA vaccine. A cross-section of a lipid nanoparticle carrying mRNA (orange) of a virus, for example, Covid-19 or influenza, is shown entering a human cell. [Kateryna Kon/Science Photo Library/Getty Images] Lipid nanoparticles may deliver better when they are a little disorganized. That’s according to new research from a study led by scientists at the University of Copenhagen that will be presented at the Biophysical Society Annual Meeting which will be held in San Francisco from February 21-25 this year.  Their research focused on lipid nanoparticles (LNPs) which were crucial to the success of mRNA…

Evelyne Bischof on why credible training of doctors in healthy longevity is one of the most important health innovations of our time. Longevity Education Hub has published the first original research paper demonstrating data on the impact of healthy longevity medicine education for physicians on their actual clinical practice. Healthy longevity medicine has been a subject of discussion for years. We talked about biomarkers, biological age, prevention frameworks, and systems thinking. The field has examined biomarkers of aging, biological age estimation, preventive care frameworks, and systems-level approaches to health optimization. Researchers and physicians have convened at numerous scientific conferences to…

Credit: Ayush Panda Researchers in India have discovered a strategy that some pathogenic bacteria, including Mycobacterium tuberculosis, use to attack immune cells before they even come into contact. Their findings show that these bacteria send out extracellular vesicles containing specialized lipids that stiffen the membranes of phagocytic cells, blocking key immune functions and allowing the invaders to evade immunity.  This research will be presented this weekend at the 70th Biophysical Society Annual Meeting in San Francisco.  Tuberculosis remains a major threat to public health, causing over a million deaths every year. M. tuberculosis, the bacterium that causes this deadly infection,…

Credit: CoreDesignKEY / iStock / Getty Images Plus As an AI practitioner, advisor, author, and speaker, the two words I use the most in my work are “done right.” Done right is a prerequisite to achieving the holy grail of artificial intelligence (AI), which is to create value at scale in service of being better at the things we care about, like improving the quality of health and medical services or reducing the cognitive burden faced by clinicians and caregivers today. In reality, most people and organizations start their AI journey by “doing things wrong.” Having said this, it’s important…

Spatial multiomics promises to significantly deepen our understanding of biology by enabling the study of cells in their native environment. After all, cells do not act in isolation—they constantly “talk” to each other and interact with their surroundings through a complex network of molecular signals. Despite the transformative power of spatial multiomics, it has been less than a decade since the field came into its own, meaning numerous challenges lay ahead for the pioneers navigating uncharted waters. Tamas Ordog, MD, professor of physiology and director of the Spatial Multiomics Core at the Mayo Clinic, believes spatial biology is “absolutely central”…

Credit: Mohammed Haneefa Nizamudeen / Getty Images Researchers at Stony Brook University have created an oral vaccine from a modified strain of Listeria monocytogenes (Lm) that can prime tumor-specific immune responses in the gut and improve control of colorectal cancer (CRC) in preclinical models. The research, published in the Journal for ImmunoTherapy of Cancer, demonstrated that the orally delivered vaccine directly targeted the gut and intestinal tissue and generated a robust anti-tumor CD 8 T cell response. “The clinical significance of our laboratory findings is underscored by the vaccine performance in treating established tumors,” said senior author Brian Sheridan, PhD,…

The drug discovery landscape is moving quickly. Computational demands are ramping up, and organizations can no longer rely on outdated intuition alone. Yet, even in some of the largest scientific collaborations, cloud infrastructure remains a gap. This raises the need for better understanding around exactly how to integrate modern practice with existing infrastructure. [Moya Studio/ E+/ Getty Images] If you’ve ever ridden a bike, pulled on a pair of rollerblades or walked a tightrope, you’ll know the importance of balance: lean too far either way and you’re in trouble. Business is no different. This is especially true in drug discovery,…

Credit: jxfzsy/Getty Images When standard chemotherapy fails in young men with germ cell tumors, options become limited and often grueling. High-dose chemotherapy can offer a second chance at durable remission, but for many, it comes at the cost of significant toxicity without long-term benefit. A new study published in the Journal of Clinical Oncology suggests that a simple blood test could help identify which patients are most likely to benefit from such intensive therapy. Investigators from the Princess Máxima Center for Pediatric Oncology, in collaboration with colleagues in Italy and Slovakia, analyzed circulating tumor DNA (ctDNA) in young adults with relapsed or…

Precision nutrition pioneer L-Nutra will bring fasting-mimicking science and clinically validated longevity programs to the Longevity Show. The Longevity Show 2026 has announced L-Nutra as an Innovator Partner, signaling the rising influence of evidence-based nutrition in extending healthspan and tackling the chronic diseases of aging. Nutrition has always been medicine’s awkward middle child – everywhere at once, yet oddly ignored. We’ve seen it relegated to flimsy patient pamphlets or over-analyzed in academic journals, but it’s rarely been treated with the kind of systematic, pharmaceutical-grade discipline that actually moves the needle. Nutrition as infrastructure Andrea Ghirardi, L-Nutra’s CEO EMEA, isn’t heading…